SIOX Sio Gene Therapies

Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Its current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. The company is also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson's disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies.

Company profile

Pavan Cheruvu
Fiscal year end
Former names
Axovant Gene Therapies Ltd., Axovant Sciences Ltd., Roivant Neurosciences Ltd.
Sio Europe Limited • Axovant Holdings Limited • Axovant Sciences GmbH ...

SIOX stock data



12 Nov 21
24 Jan 22
31 Mar 22
Quarter (USD)
Sep 21 Jun 21 Mar 21 Dec 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Mar 21 Mar 20 Mar 19 Mar 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 102.88M 102.88M 102.88M 102.88M 102.88M 102.88M
Cash burn (monthly) 3.09M (positive/no burn) 7.08M 3.92M 3.09M 3.6M
Cash used (since last report) 11.81M n/a 27.03M 14.98M 11.8M 13.74M
Cash remaining 91.06M n/a 75.84M 87.9M 91.08M 89.14M
Runway (months of cash) 29.4 n/a 10.7 22.4 29.5 24.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
8 Dec 21 Nassif David W. Common Stock Payment of exercise Dispose F No No 1.42 6,294 8.94K 45,244
8 Dec 21 Nassif David W. Common Stock Grant Acquire A No No 0 17,534 0 51,538
8 Dec 21 Nassif David W. RSU Common Stock Sale back to company Dispose D No No 0 17,534 0 35,066
8 Dec 21 Cheruvu Pavan Common Stock Payment of exercise Dispose F No No 1.42 14,884 21.14K 203,109
8 Dec 21 Cheruvu Pavan Common Stock Grant Acquire A No No 0 37,567 0 217,993
8 Dec 21 Cheruvu Pavan RSU Common Stock Sale back to company Dispose D No No 0 37,567 0 75,133
15 Apr 21 Cheruvu Pavan Stock Option Common Stock Grant Acquire A No No 2.47 682,100 1.68M 682,100
15 Apr 21 Corcoran Gavin Stock Option Common Stock Grant Acquire A No No 2.47 244,300 603.42K 244,300
15 Apr 21 Nassif David W. Stock Option Common Stock Grant Acquire A No No 2.47 239,000 590.33K 239,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

0.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 1
Opened positions 1 1
Closed positions 1 0 NEW
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 5K 1.6M -99.7%
Total shares 1 9.04K -100.0%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
BNP Paribas Arbitrage 1 $5K NEW
Largest transactions
Shares Bought/sold Change
Tower View Investment Management & Research 0 -9.04K EXIT
BNP Paribas Arbitrage 1 +1 NEW
IFP Advisors 0 0

Financial report summary

  • We have a limited operating history and have never generated any product revenues.
  • Our business, operations and clinical development plans and timelines could continue to be adversely impacted by the effects of health epidemics, including the recent COVID-19 pandemic, on the manufacturing, clinical trial and other business activities performed by us or by third parties with whom we conduct business, including our contract manufacturers, contract research organizations, or CROs, shippers and others.
  • We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.
  • We are heavily dependent on the success of our gene therapy product candidates, which are still in early stages of clinical development. If we are unable to successfully develop and commercialize any of our product candidates, our business will be harmed.
  • We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates.
  • Raising additional funds by issuing securities may cause dilution to existing stockholders, raising additional funds through debt financings may involve restrictive covenants, and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.
  • We may be required to continue to make significant payments to third parties under the agreements pursuant to which we acquired our gene therapy product candidates.
  • Our business plan may lead to the initiation of one or more gene therapy development programs, the discontinuation of one or more development programs, or the execution of one or more transactions that you do not agree with or that you do not perceive as favorable to your investment.
  • We may not be able to manage our business effectively if we are unable to attract and retain key personnel. In addition, if we are unable to effectively transition and integrate our new executive officers, our business and financial performance could be adversely affected.
  • Our employees, independent contractors, principal investigators, consultants, commercial collaborators, manufacturers, service providers and other vendors, or those of our affiliates, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.
  • Operation of our business internationally exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business in various jurisdictions globally.
  • The withdrawal of the United Kingdom, or the U.K., from the European Union, or the E.U., commonly referred to as “Brexit”, may adversely impact our ability to obtain regulatory approvals of our product candidates in the U.K. or the EU and may require us to incur additional expenses to develop and commercialize our product candidates in the U.K. or the EU or receive clinical supply of our product candidates from manufacturing partners in the U.K.
  • Use of social media platforms presents new risks.
  • The failure to maintain our current enterprise resource planning system ("ERP") could adversely impact our business and results of operations.
  • Potential product liability lawsuits against us could cause us to incur liabilities and limit commercialization of any products that we may develop.
  • Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
  • We are subject to stringent U.S. and foreign privacy laws, regulations and standards related to data privacy and security. If we fail to comply with such requirements, we may be subject to liabilities that adversely affect our business, operations and financial performance, disruption to our clinical trials or the commercialization of our products, and/or harm to our reputation.
  • We may not be successful in our efforts to identify and acquire additional gene therapy product candidates, or to enter into collaborations or strategic alliances for the development and commercialization of any such future product candidates.
  • Clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome.
  • Interim "top-line" and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.
  • We face significant competition from other biotechnology and pharmaceutical companies, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours and our operating results will suffer if we fail to compete effectively.
  • If we are not able to obtain required regulatory approvals, we will not be able to commercialize our gene therapy product candidates, and our ability to generate revenue will be materially impaired.
  • Our gene therapy product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.
  • Our AAV-based gene therapy product candidates and our lentiviral-based gene therapy product candidate are based on new gene transfer technology, which makes it difficult to predict the time and cost of product candidate development and of subsequently obtaining regulatory approval.
  • Even if we obtain FDA approval for our gene therapy product candidates in the United States, we may never obtain approval for or commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential.
  • Even if we obtain regulatory approval for our product candidates, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.
  • Even if our product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.
  • Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.
  • Increasing demand for compassionate use or expanded access of our unapproved therapies could negatively affect our reputation and harm our business.
  • If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates, even if approved.
  • If the market opportunities for any product candidates we may develop are smaller than we believe they are, our revenues, if any, may be adversely affected, and our business may suffer. Because the target patient populations for many of the product candidates we may develop are small, we must be able to successfully identify patients and achieve a significant market share to achieve and maintain profitability and growth.
  • If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.
  • Our current and future relationships with investigators, health care professionals, consultants, third-party payors, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
  • Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
  • Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell our products profitably, if approved.
  • Gene therapies are novel, complex, difficult and expensive to manufacture. We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of our product candidates.
  • Any contamination in our manufacturing process, shortages of raw materials or failure of any of our key suppliers to deliver necessary components could result in delays in our clinical development or marketing schedules.
  • We intend to rely on third parties to conduct, supervise and monitor our nonclinical studies and our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.
  • We may seek to enter into collaborations in the future with other third parties. If we are unable to enter into such collaborations, or if these collaborations are not successful, our business could be adversely affected.
  • If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.
  • If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent term and obtain data exclusivity for our product candidates, our business may be materially harmed.
  • The validity, scope and enforceability of any patents that cover our biologic product candidates can be challenged by third parties.
  • We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
  • Third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights may delay or prevent the development and commercialization of our product candidates.
  • We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.
  • If we breach any of our license or collaboration agreements, it could compromise our development and commercialization efforts for our product candidates.
  • Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology.
  • We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.
  • Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.
  • Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We may not be able to protect our intellectual property rights throughout the world, which could impair our business.
  • Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.
  • Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • An active trading market for our common stock may not be sustained.
  • The market price of our common stock has been and is likely to continue to be highly volatile, and you may lose some or all of your investment.
  • Volatility in our stock price could subject us to securities class action litigation.
  • RSL owns a significant percentage of our shares of common stock and is able to exert significant control over matters subject to stockholder approval.
  • Our organizational and ownership structure may create significant conflicts of interests.
  • Because we do not anticipate paying any cash dividends on shares of our common stock in the foreseeable future, capital appreciation, if any, would be your sole source of gain.
  • Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result.
  • Our certificate of incorporation and bylaws provide that the Court of Chancery of the State of Delaware or, under certain circumstances, the federal district courts of the United States of America are the exclusive forums for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.
  • Your rights as a stockholder arise under Delaware law as well as our Delaware certificate of incorporation and bylaws.
  • Future sales of shares of our common stock, or the perception that such sales may occur, could depress our stock price, even if our business is doing well.
  • If we are unable to maintain proper and effective internal controls over financial reporting and disclosure controls and procedures, investor confidence in our company and, as a result, the value of our common stock, may be adversely affected.
  • We are a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors.
  • The intended tax effects of our corporate structure prior to and following the Domestication and our corporate reorganization to align our corporate structure with current and future business activity (the "Reorganization"), and intercompany arrangements prior to the Domestication and Reorganization, depend on the application of the tax laws of various jurisdictions and on how we operate our business.
  • Changes in our effective tax rate may reduce our net income in future periods.
  • Changes in tax laws in the United States or foreign jurisdictions could materially increase our tax expense.
  • Our business and operations would suffer in the event of system failures, security breaches or cyber-attacks.
  • If securities or industry analysts cease to publish research or reports about our business, or publish negative reports about our business, our stock price and trading volume could decline.
  • We have incurred and will continue to incur substantial costs as a result of operating as a public company, and our management has been and will be required to continue to devote substantial time to compliance with our public company responsibilities and corporate governance practices.
Content analysis
H.S. junior Avg
New words: advice, complement, escalation, ESGCT, Fast, focal, forward, MAAC, overhead, overt, rental, resigned, Track, variant, ventricular, Virtual
Removed: abnormal, academic, accumulation, age, agonist, aim, akinesia, alpha, altering, ameliorated, architecture, aspartate, assessing, AST, balanced, barrier, basal, beta, bicistronic, biochemical, birth, blood, bradykinesia, buildup, capsid, carbidopa, catechol, characterizing, child, chronic, CNS, cofactor, cognitive, collaborated, colocalization, compatible, COMT, configuration, construct, continuously, convert, copy, cure, Cyclohydrolase, defect, destruction, developmental, digit, diligent, dimer, directing, Distinguishing, dopamine, dual, durable, dyskinesia, element, emergent, emission, empty, encode, endoscopic, endpoint, ensuing, enteral, enzymatic, essential, exact, exam, exhibited, expectancy, experimentation, expression, fatal, feline, Fibrin, flexible, France, Functionally, fusion, gal, ganglia, gastrostomy, generator, goal, guided, headache, Hex, HEXA, HEXB, hexosaminidase, Hydroxylase, hypo, imitation, Impression, improve, improving, impulse, indwelling, infection, infusion, inhibitor, intravenously, involuntary, jejunal, Lancet, Lang, linker, live, locomotor, lumbar, mainstay, marked, median, metabolism, mid, modulate, Molecular, monoamine, mortality, mouse, MRI, multifactorial, murine, nerve, neural, neurodegeneration, neurodevelopmental, neuromuscular, neurotropic, nutritional, occurrence, optimal, oral, ordering, orphan, oxidase, paper, pathophysiological, payload, peripheral, perpetual, pertinent, PET, positron, postural, precursor, primate, privately, progressive, putamen, radiotracer, ranging, ratio, receptor, reducing, region, registrational, regression, removal, responsive, restored, restoring, retained, retrospective, reveal, rigidity, role, selected, sham, shareholder, signaling, statistically, stimuli, stoichiometry, striatal, striatum, studying, subthalamic, subunit, surgically, survival, symptomatic, synthesize, systemic, Tetrahydrobiopterin, tiered, timepoint, tomography, tonic, transduce, transferase, transient, transparent, treat, tremor, TU, tube, twelve, typical, tyrosine, underwent, uniformly, untreated, utilize, vivo, wearing, week, wrong, yearly